Lipigon Pharmaceuticals AB (publ) (STO:LPGO)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.305
+0.013 (4.28%)
Mar 25, 2025, 1:32 PM CET
-21.11%
Market Cap 43.31M
Revenue (ttm) 8.97M
Net Income (ttm) -22.11M
Shares Out 148.33M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 540,369
Average Volume 1,518,748
Open 0.300
Previous Close 0.292
Day's Range 0.295 - 0.310
52-Week Range 0.086 - 0.401
Beta 0.86
RSI 76.26
Earnings Date Feb 21, 2025

About STO:LPGO

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company’s product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol LPGO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.